Over 1,200 Xarelto lawsuits are pending in a multidistrict litigation in the U.S. District Court for the Eastern District of Louisiana. Xarelto plaintiffs allege that the anticoagulant drug’s manufacturers, including Bayer HealthCare Pharmaceuticals and Johnson & Johnson’s Janssen Pharmaceutical, did not provide patients and doctors with adequate warning about Xarelto’s severe bleeding risks.
Approved by the U.S. Food and Drug Administration (FDA) in ...
continue reading...
Pharmaceutical giant AstraZeneca has been given the go-ahead to market a new, 60-milligram dose of their blood thinner Brilinta for longer-term use in patients who have suffered heart attacks. According to Reuters, the U.S. Food and Drug Administration (FDA) approved the new dose for use along with aspirin at any time after a heart attack. Brilinta, an antiplatelet drug used to prevent blood clots, was previously available only at a higher dosage, and ...
Janssen Pharmaceuticals and Bayer have long insisted their blood-thinning drug Xarelto is a safer, more reliable alternative to the decades-old warfarin. However, a new study recently published in the American Heart Association’s journal Circulation suggests the popular “new-age” anticoagulant may be no safer than warfarin in terms of bleeding in elderly patients.
Xarelto was approved by the U.S. Food and Drug Administration in 2011 ...
continue reading...Xarelto has long been associated with severe bleeding, but according to a new study, the popular blood thinner may also pose a risk to pregnant women and their unborn babies. The study, published last month by the American Journal of Obstetrics and Gynecology, examined the way in which rivaroxaban (Xarelto) is transported across the placenta of a pregnant woman.
Current Xarelto lawsuits focus on the risk severe bleeding, ...
continue reading...A new study has been published by the Journal of the American Medical Association Opthalmology linking use of the anticoagulant Xarelto (rivaroxaban) to eye bleeding. The study, conducted by Retina Associates of Orange County in Laguna Hills, California, observes three patients who developed spontaneous vitreous hemorrhage after starting use of Xarelto. The researchers note that all three patients were tapering off another anticoagulant at the time of their ...
A Wisconsin woman has filed a Xarelto lawsuit against multiple pharmaceutical companies for damages allegedly resulting from the anticoagulant drug. The plaintiff states that the defendants, including Bayer Healthcare and Johnson & Johnson’s Janssen Pharmaceuticals, did not adequately warn doctors and patients of the risk of uncontrollable bleeding that Xarelto poses. The Xarelto lawsuit further claims that the drug’s manufacturers failed to provide appropriate instructions on how to intervene should serious ...
